RELB Antikörper (C-Term) (Biotin)

Produktnummer ABIN8053148

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch RELB in WB, IHC und ELISA. Es zeigt Reaktivität gegenüber Proben von Human, Maus und Ratte.

Kurzübersicht für RELB Antikörper (C-Term) (Biotin) (ABIN8053148)

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser RELB Antikörper ist konjugiert mit Biotin

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Produktdetails anti-RELB Antikörper (Biotin)

Bindungsspezifität: C-Term

Verwendungszweck: Anti-Rel B/RELB Antibody Biotin Conjugated

Spezifität: No cross reactivity with other proteins.

Kreuzreaktivität (Details): No cross-reactivity with other proteins

Homologie: identical to the related mouse sequence.

Aufreinigung: Immunogen affinity purified.

Immunogen: A synthetic peptide corresponding to a sequence at the C-terminus of human Rel B, identical to the related mouse sequence.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, Optimal dilutions should be determined by end users. Immunohistochemistry (Paraffin-embedded Section), Optimal dilutions should be determined by end users. ELISA, Optimal dilutions should be determined by end users.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Each vial contains 50 % glycerol, 0.9 % NaCl, 0.2 % Na2HPO4, 0.02 % Sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: At -20°C for one year from date of receipt. Avoid repeated freezing and thawing.

Haltbarkeit: 12 months

Details zu RELB

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Andere Bezeichnung: RELB

Hintergrund:

Background: RELB (v-rel reticuloendotheliosis viral oncogene homolog B) is also known as IREL. The International Radiation Hybrid Mapping Consortium assigned the RELB gene to chromosome 19. By RT-PCR and immunocytochemical analyses, Clark et al. (1999) showed that RELB expression correlated with dendritic cell activation. NF-kappa-B-inducing kinase is required for osteoclastogenesis in response to pathologic stimuli. Vaira et al. (2008) found that overexpression of Relb, but not Rela, rescued differentiation of mouse Nik -/- osteoclast precursors, indicating that blockade of the alternative NF-kappa-B pathway, rather than the classical NF-kappa-B pathway, is responsible for the osteoclastogenic defect in the absence of Nik. Using Relb -/- mice, they showed that Relb itself was required for Rankl-induced osteoclastogenesis in vitro and for TNF-induced bone resorption in vivo. Both Relb -/- and Nik -/- mice were resistant to tumor-mediated osteolysis. Vaira et al. (2008) concluded that the alternative NF-kappa-B pathway, via RELB, plays an essential and unique role in RANKL signaling toward osteoclast development.

Gene Full Name: RELB proto-oncogene, NF-kB subunit

Sequence Similarities: Contains 1 RHD (Rel-like) domain.

Gen-ID: 5971

UniProt: Q01201

Pathways: NF-kappaB Signalweg, RTK Signalweg